Stock Events

Stock Events

Bone Biologics 

$12.00
34
-$3.50-22.58% Today

Statistics

Day High
12
Day Low
12
52W High
35.95
52W Low
8.3
Volume
503
Avg. Volume
192
Mkt Cap
21.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.24
-2.27
-1.29
-0.32
Expected EPS
-0.39
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.65MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLGW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stryker
SYK
Mkt Cap119.69B
Stryker Corporation is a leading medical technology company that offers a range of orthopedic products, competing directly with Bone Biologics in the bone repair and regeneration market.
Zimmer Biomet
ZBH
Mkt Cap17.13B
Zimmer Biomet Holdings, Inc. specializes in musculoskeletal healthcare, offering products that compete in the orthopedic sector, similar to Bone Biologics' offerings.
Medtronic
MDT
Mkt Cap102.97B
Medtronic plc provides medical technologies, services, and solutions, including bone healing and regeneration products, making it a competitor in the same space as Bone Biologics.
Boston Scientific
BSX
Mkt Cap69.72B
Boston Scientific Corporation offers products in various medical fields, including orthopedic surgery, competing with Bone Biologics in areas like bone growth and repair.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers a wide range of orthopedic products, directly competing with Bone Biologics in the field of bone health and regeneration.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc., while primarily known for its biopharmaceutical products, has ventured into cell therapy, which could potentially compete with Bone Biologics' regenerative medicine approaches.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc., with its broad range of healthcare products, has the potential to compete in the orthopedic and regenerative medicine space, overlapping with Bone Biologics' market.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including treatments that could compete with Bone Biologics in bone health and regeneration.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. focuses on human therapeutics, including osteoporosis treatment and bone health products, making it a competitor in the bone regeneration market alongside Bone Biologics.

About

Bone Biologics Corporation is a medical device firm dedicated to revolutionizing bone regeneration, particularly within spinal fusion procedures. The company's primary innovation is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein. This bio-engineered protein offers precise, targeted control over new bone formation. Currently, Bone Biologics is advancing the NELL-1/DBX Fusion Device, specifically engineered for spinal fusion applications in skeletally mature patients suffering from degenerative disc disease, focusing on single-level fusions from L4 to S1. Beyond spinal applications, the versatility of its foundational technology promises to deliver improved outcomes across various surgical disciplines, including general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Underpinning its development, the company holds a licensing agreement with the UCLA Technology Development Group to further develop and commercialize NELL-1 for spinal fusion. Established in 2004, Bone Biologics Corporation is headquartered in Burlington, Massachusetts.
Show more...
CEO
Mr. Jeffrey Frelick
Employees
2
Country
United States
ISIN
US0980701546

Listings

XNAS
US
BBLGW
XNAS
US
BBLG
BOATS
BOATS
BBLG.BOATS

0 Comments

Share your thoughts

FAQ

What is Bone Biologics stock price today?▼
The current price of BBLGW is $12.00 USD — it has decreased by -22.58% in the past 24 hours. Watch Bone Biologics stock price performance more closely on the chart.
What is Bone Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bone Biologics stocks are traded under the ticker BBLGW.
Is Bone Biologics stock price growing?▼
BBLGW stock has fallen by -14.29% compared to the previous week, the month change is a -39.7% fall, over the last year Bone Biologics has showed a -11.11% decrease.
What is Bone Biologics market cap?▼
Today Bone Biologics has the market capitalization of 21.54M
When is the next Bone Biologics earnings date?▼
Bone Biologics is going to release the next earnings report on September 02, 2026.
What were Bone Biologics earnings last quarter?▼
BBLGW earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.43 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bone Biologics revenue for the last year?▼
Bone Biologics revenue for the last year amounts to 0 USD.
What is Bone Biologics net income for the last year?▼
BBLGW net income for the last year is -14.65M USD.
How many employees does Bone Biologics have?▼
As of June 16, 2026, the company has 2 employees.
In which sector is Bone Biologics located?▼
Bone Biologics operates in the Health & Wellness sector.
When did Bone Biologics complete a stock split?▼
The last stock split for Bone Biologics was on June 10, 2025 with a ratio of 1:6.
Where is Bone Biologics headquartered?▼
Bone Biologics is headquartered in Burlington, United States.